Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

102.89
+1.291.27%
Post-market: 102.890.00000.00%19:31 EDT
Volume:650.45K
Turnover:66.78M
Market Cap:5.08B
PE:-17.83
High:103.83
Open:101.13
Low:100.00
Close:101.60
Loading ...

Axsome Therapeutics Q1 Adj. EPS $(0.68) Beats $(1.33) Estimate, Sales $121.46M Beat $119.87M Estimate

Benzinga
·
05 May

Earnings Flash (AXSM) Axsome Therapeutics Posts Q1 Net Loss $1.22 a Share, vs. FactSet Est of $1.31 Loss

MT Newswires Live
·
05 May

BRIEF-Axsome Therapeutics Q1 Net Income USD -59.413 Million

Reuters
·
05 May

Axsome Therapeutics Q1 Operating Expenses USD 178.445 Million

THOMSON REUTERS
·
05 May

Axsome Therapeutics Q1 Total Net Product Revenue Was $121.5 Million

THOMSON REUTERS
·
05 May

Axsome Therapeutics Q1 EPS USD -1.22

THOMSON REUTERS
·
05 May

North American Morning Briefing: Stock Futures Down As Oil Plunges

Dow Jones
·
05 May

Axsome Therapeutics (AXSM) Gets a Buy from Mizuho Securities

TIPRANKS
·
02 May

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

GlobeNewswire
·
01 May

Axsome Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
30 Apr

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Alnylam Pharma (ALNY)

TIPRANKS
·
29 Apr

Axsome Therapeutics Inc : RBC Raises Target Price to $193 From $190

THOMSON REUTERS
·
29 Apr

UBS Adjusts Axsome Therapeutics Price Target to $143 From $149, Maintains Buy Rating

MT Newswires Live
·
28 Apr

Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
22 Apr

Top Analyst Reports for Apple, Philip Morris & Sony

Zacks
·
18 Apr

Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?

Zacks
·
10 Apr

Top Research Reports for Verizon, The Southern Co. & Blackstone

Zacks
·
08 Apr

Axsome Therapeutics Initiated at Buy by Jefferies

Dow Jones
·
07 Apr

Axsome Therapeutics: Promising CNS Pipeline and Growth Potential Justify Buy Rating

TIPRANKS
·
07 Apr

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

GlobeNewswire
·
04 Apr